The oral small-molecule glucagon-like peptide-1 receptor agonist, orforglipron, reduced glycated hemoglobin (HbA1c) over 40 ...

Amycretin, a new weight-loss treatment from Novo Nordisk, combines two hunger hormones, helping participants lose nearly ...

Researchers found that the active ingredient in Ozempic may lower the risk of dementia in people with type 2 diabetes.

Researchers at the Case Western Reserve School of Medicine have found that semaglutide, a popular diabetes and weight-loss ...

OPKO Health and Entera Bio Abstract for First-in-Class Dual GLP-1/Glucagon Tablet Candidate for Patients with Obesity and ... and a weekly injectable variant of the same molecule, ...

Collaboration combines Novo Nordisk’s scientific leadership in obesity and cardiometabolic diseases with Septerna’s expertise in G protein-coupled receptor (GPCR) drug discovery Goal is to ...

The molecule reviewed in the October 17th press release demonstrated 80% bioavailability relative to ... provided a look at new preclinical data for a glucagon-like peptide-1 (GLP-1) incretin ...

Biomea Fusion Inc. has released preclinical findings from a 28-day weight loss study in obese nonhuman primates evaluating ...